What does the advice say about biologic therapy, or body-material joint shots?

Why don't all reports agree?

The reports ask different questions. Some cover daily care, while others compare the PRP shot with another shot or a salt-water shot.

Clinics also prepare PRP in different ways. They may keep different amounts of clot-making platelets and white blood cells or use a different number of visits.

That difference matters. A result for one PRP preparation in one knee can't settle what will happen in every joint.

What do the limits mean for me?

First, find the cause. Your joint, its wear, and the tasks you can't do matter more than a sales claim.

PRP has more support than shots made from marrow or body fat. Even a careful study can't tell you what result you'll get.

Keep up safe exercise. Do the strength moves your doctor or physical therapist gave you, and walk only as far as the joint allows.

Extra weight can add strain. If that applies to you, ask your doctor for a safe and realistic way to lose some.

What should I ask before I decide?

Ask what caused the soreness first. Then ask whether the report studied your joint with about the same amount of wear.

Get the likely cost and recovery time. Don't accept an answer that skips risks, limits on activity, or another choice that may fit.

Bring your questions and medicine list. At QC Kinetix, medical providers examine the joint and discuss regenerative treatments, meaning joint procedures made from body material.

Sources

1. The AAOS third-edition clinical practice guideline on non-arthroplasty management of knee osteoarthritis contains 29 recommendations and explicitly highlights intra-articular corticosteroid, hyaluronic acid AND platelet-rich plasma as the areas where better research is still needed - including osteoarthritis characterisation, subgroup and severity stratification, control for bias, and cost-effectiveness analysis.

   Brophy RH, Fillingham YA. — AAOS Clinical Practice Guideline Summary: Management of Osteoarthritis of the Knee (Nonarthroplasty), Third Edition.. Journal of the American Academy of Orthopaedic Surgeons, 2022. DOI: 10.5435/JAAOS-D-21-01233.

2. The AAOS patient-education FAQ on orthobiologics states that because orthobiologics are relatively new the evidence supporting their use is LIMITED, that rigorous testing of effectiveness in most orthopedic conditions is lacking, and that preliminary results are encouraging but hard to evaluate. It names tendinopathies such as tennis elbow, pain from early knee osteoarthritis, adjunct healing after rotator cuff repair, and avascular necrosis as the settings where biologic therapies have shown promise, and notes that stem cell treatments not derived from the patient's own body and further manipulated in a laboratory can only be offered inside an FDA-approved clinical trial.

   American Academy of Orthopaedic Surgeons — Orthobiologics (Regenerative Medicine) FAQ. OrthoInfo (AAOS), 2024.

3. The ESSKA-ORBIT European consensus on blood-derived orthobiologics graded 28 question-statement sets; only 9 of 28 had high-level scientific support. Three statements reached grade A: that there is enough preclinical and clinical evidence to support PRP use in knee OA; that clinical evidence shows effectiveness in MILD TO MODERATE knee OA (KL grade 3 or lower); and that PRP provides a longer effect than the short-term effect of corticosteroid with a safer profile. The panel regarded PRP as a valid and possible first-line injectable option for KL grades 1-3.

   Laver L, et al. — The use of injectable orthobiologics for knee osteoarthritis: A European ESSKA-ORBIT consensus. Part 1-Blood-derived products (platelet-rich plasma).. Knee Surgery, Sports Traumatology, Arthroscopy, 2024. DOI: 10.1002/ksa.12077.

4. The companion ESSKA-ORBIT consensus on cell-based therapy (77 experts, 22 countries, 27 statements) found only 5 of 27 statements reached recommendation level A or B; 22 were rated C or D. It concluded that cell-based therapy shows clinical benefit in pain and function up to 12 months for KL grades 1-3 with some benefit in selected KL 4, but that because of limited high-quality studies and NO clear superiority over other injectables it should be considered a SECOND-LINE option, after other non-operative treatment fails.

   de Girolamo L, et al. — The use of injectable orthobiologics for knee osteoarthritis: A formal ESSKA-ORBIT consensus. Part 2-Cell-based therapy.. Knee Surgery, Sports Traumatology, Arthroscopy, 2025. DOI: 10.1002/ksa.70001.

5. The 2025 Cochrane review of stem cell injections for knee osteoarthritis pooled 25 randomised trials (1,341 participants) and found that, compared with placebo injection, stem cell injection MAY slightly improve pain (1.2 points better on a 0-10 scale, 7 studies, 445 participants) and function (14.2 points better on a 0-100 scale, 7 studies, 432 participants) up to six months - both rated LOW-certainty evidence, downgraded for indirectness (cell source, preparation and dose varied across studies) and suspected publication bias, since up to three larger RCTs were conducted and withdrawn before reporting results. Radiographic progression was not assessed in any included study.

   Whittle SL, et al. — Stem cell injections for osteoarthritis of the knee.. Cochrane Database of Systematic Reviews, 2025. DOI: 10.1002/14651858.CD013342.pub2.

6. A systematic mapping of the entire injectable knee OA literature since 1959 identified 766 clinical studies covering 75,834 patients: 11,245 treated with corticosteroid, 40,862 with hyaluronic acid, 16,174 with PRP and 7,553 with cell-based therapies. Hyaluronic acid still has the largest evidence base; PRP has recently overtaken corticosteroid in number of studies; placebo-controlled RCTs remain limited and only a negligible percentage of studies examined disease-modifying effects.

   Bensa A, et al. — Corticosteroids, hyaluronic acid, platelet-rich plasma, and cell-based therapies for knee osteoarthritis - literature trends are shifting in the injectable treatments' evidence: a systematic review and expert opinion.. Expert Opinion on Biological Therapy, 2025. DOI: 10.1080/14712598.2025.2465833.